Loading
HH
Hainan Huluwa Pharmaceutical Group Co., Ltd. Stock: price and insider trades · China
ST葫芦娃
No insider purchase over the last 90 days. The latest, by 吴雪雯, was filed 24 Nov 2022.
Hainan Huluwa Pharmaceutical Group Co., Ltd.: what insiders have been doing
Every trade that managers of Hainan Huluwa Pharmaceutical Group Co., Ltd. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector. The past year has been quiet: not a single insider filing for Hainan Huluwa Pharmaceutical Group Co., Ltd. The previous disclosure was published on 28 November 2022.
The full history, which starts in 2022, counts 3 purchases against 1 sale.
In the same sector, recent insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. also feature in our signals. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
Insider Decl.
4
Thresholds
n/a
Buy Volume
€13,854
3 ops. · all time
Sell Volume
€5,735
1 ops. · all time
Since the insiders bought
- +6.8%Entry CN¥17.84 · Close at T+365 CN¥19.06
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,309 of 23,476 companies
25.5
score / 100
Value33
Quality18
FCF yld2.3%
Earn yld-12%
EV/EBITDA·
ROE-73%
Gross mgn29%
Net mgn-32%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥5.83
Analyst consensus
Income statement
RevenueCN¥900.8M
Gross profitCN¥264.4M29% margin
EBITDA-CN¥127.9M-14% margin
Net income-CN¥287.4M-63.6% margin
Valuation
P/Book7.8x
Beta0.34
Balance sheet & cash
Market capCN¥2.3B
Total debtCN¥1.2B
Free Cash FlowCN¥53.2M
Debt / Equity274%
Profitability & ownership
ROE-73.3%
ROA-8.6%
% insiders72.9%
% institutions1.0%
Last declaration on 28 November 2022
Declarations4 total
4 of 4 declarations
About Hainan Huluwa Pharmaceutical Group Co., Ltd.
ST葫芦娃 is a company listed on the XSHG market, specializing in the health and pharmaceutical sector. It focuses on the development and commercialization of innovative solutions for patient well-being.
